Late Breaking Abstracts

• Call for Abstracts
• For Invited Speakers
• Conflict of Interest
• Result
• Late Breaking Abstracts
• Embargo Policy

Outline

We will be accepting “Late Breaking Abstracts” in this meeting to provide a forum for reports on the very latest research outcomes that became available after the general abstract submission period. Please see details below. We look forward to receiving your submissions!

Embargo Policy

Please click here for the Embargo Policy of the Japan College of Rheumatology.

Eligibility for Submission

Non-Japanese Citizens who are JCR members

• Please send your number of JCR member to the secretariat after abstract submission.
• There is no age limit for abstract submission.

New Submission, Review and Modify

Late Breaking Abstracts Submission, Review and Modify

• If you are a JCR member, please access the online member site and log in to your page. You can submit your abstract on your page.
• Applicants cannot submit the same abstract to both English and Japanese Submission Systems.
  (i.e. it can be submitted ONLY through either English or Japanese system)
• If you are a Japanese JCR member or Japanese living abroad, please use the Japanese system.

Abstract Requirements

• Abstracts must be of original work and may be acceptable if containing some additional information to those presented or published anywhere prior to JCR2025.
• Please describe drugs with general name instead of drug name.
• Accepted late breaking abstracts to JCR2025 will be published in "Mobile App for JCR2025 Abstracts".
• Applicants cannot submit the same abstract to both English and Japanese Submission.
  (i.e. it can be submitted ONLY through either English or Japanese)
• Abstracts may be rejected as the result of abstract review for reasons such as: contents not well organized (e.g. Section paragraphs [Object, Methods, Results, and Conclusions] are not specified), contents seen to be not suitable for presentation in JCR2025, and so on.
• Please refrain from including the names of co-presenters in the body of the abstract.

Abstract Structure

• Objectives
• Methods
• Results
• Conclusion

Notes:

*No graphs, tables, or images can be included in abstracts.

*If the abstract contents are a case report, please clearly state the clinical significance of the study.

Abstract Length

Please keep your abstract length within the following limits.

Notes:

*First author is considered as the presenting as well as corresponding author.

*Please do not include authors' information within abstract body. Any authors' information within abstract body may be deleted from publication.

*Though no word limit is set for "Abstract Title", "Authors" and "Affiliations", the contents of the abstract may be printed in small font size if the total letter number is too large.

List of Categories

Please submit an abstract to one of the following categories.

• Clinical: Rheumatoid Arthritis (RA)
• Clinical: Diseases Other than RA
• Translational research & Basic

Conflict of Interest (COI)

The first author of an abstract for the JCR annual meeting must declare any financial or personal relationships that may pose conflicts of interest upon acceptance for presentation at the annual meeting.
Please refer to the COI page for COI declaration requirements.

About COI Declaration

Other Important Points

If you wish to withdraw your abstract, please contact the Congress Secretariat via email (jcr2025-abs@congre.co.jp) during the submission period.

Late Breaking Abstracts Review

All submitted abstracts will be reviewed.
Abstracts may be allocated to “Late Breaking Abstracts Poster Viewing” or rejected according to the result of abstract review.

Result of Abstract Review

The result of the abstract review will be announced around the end of March to your registered email address as well as on the JCR2025 website.

Inquiries